Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 1 RP of EGFR-TKIs related studies

From: Re-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy

Drugs

Study

Published year

study type

No. of cases

Radiation dose(Gy)

RP rate(%)

First-generation EGFR-TKIs

Xu K [41]

2021

Retrospective study

45

50–66

37.7

Chih-Chia Chang [42]

2011

Clinical Trial

25

40–50

84.0

 > 3Grade: 12.0

Caicun Zhou [43]

2018

Retrospective study

145

33–60

 > 3Grade: 7.7

Jianguo Sun [44]

2019

Clinical Trial

10

54–60

40.0

 > 3Grade: 20.0

Wenxiao Jia [49]

2021

Retrospective study

67

50–60

44.78

 > 3Grade: 8.9

C Yong [45]

2016

Clinical Trial

316

40–65

15.1

Erlotinib

Zhuang H [46]

2014

Retrospective study

24

44–46

36.0

 > 3Grade: 21.0

Gefitinib

Rothschild S [47]

2011

Clinical Trial

14

63

14.0

Okamoto I [48]

2011

Clinical Trial

9

60

28.0

Oxitinib

Wenxiao Jia [57]

2021

Retrospective study

11

60

63.6

Crizotinib

Hou H [61]

2019

Meta-analysis

/

/

4.2

  1. RP Radiation pneumonitis, EGFR-TKI Epidermal Growth Factor Receptor-Tyrosine Kinase inhibitor